Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CDC25A | P30304 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | S100A4 | P26447 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | FGR | P09769 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859810 | 1.00 | CDC25B (0.56) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL25706387 | 0.84 | RAB9A (0.52) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL11573761 | 0.83 | S100A4 (0.50) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL29563346 | 0.82 | RAB9A (0.68) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL571026 | 0.82 | CDC25B (0.68) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL1510327 | 0.82 | RAB9A (0.68) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL29941466 | 0.82 | CDC25B (0.68) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| Water SCHEMBL8664586 | 0.79 | CDC25B (0.65) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL18059577 | 0.79 | ALDH1A1 (0.46) | CDC25BNPC1RAB9AALDH1A1CDC25A | |
| SCHEMBL15491792 | 0.77 | CDC25B (0.62) | CDC25BNPC1RAB9AALDH1A1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866692-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-09-30 | — | — | EP | claimed |
| WO-1997021432-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA, S.A. (FR) | 1997-06-19 | — | — | WO | claimed |
| EP-4333135-A1 | LIPOLYSIS DEVICE, LIPOLYSIS METHOD, AND ELECTRIC POWER GENERATION METHOD | Murata Manufacturing Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20230398008-A1 | LIPOLYSIS DEVICE, LIPOLYSIS METHOD, AND ELECTRIC POWER GENERATION METHOD | MURATA MANUFACTURING CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| CN-116941078-A | Fat decomposition device, fat decomposition method, and power generation method | 株式会社村田制作所 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022230464-A1 | LIPOLYSIS DEVICE, LIPOLYSIS METHOD, AND ELECTRIC POWER GENERATION METHOD | 株式会社村田製作所 | 2022-11-03 | — | — | WO | disclosed |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | disclosed |
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-08-27 | — | — | US | disclosed |
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| EP-2157652-A1 | FUEL CELL AND ELECTRONIC EQUIPMENT | Sony Corporation (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-2131437-A1 | ENZYME IMMOBILIZED ELECTRODE, FUEL CELL, ELECTRONIC EQUIPMENT, ENZYME REACTION UTILIZATION APPARATUS, AND ENZYME IMMOBILIZED BASE | Sony Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090053579-A1 | NOVEL POWER SUPPLY DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SONY CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2028712-A2 | Biofuel cell, method for producing the same, electronic apparatus, enzyme-immobilized electrode, and method for producing the same | Sony Corporation (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20090047567-A1 | Biofuel cell, method for producing the same, electronic apparatus, enzyme-immobilized electrode, and method for producing the same | SONY CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090047550-A1 | METHOD FOR MANUFACTURING FUEL CELL, FUEL CELL, AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080280184-A1 | FUEL CELL, METHOD FOR MANUFACTURING FUEL CELL, AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-0866692-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997021432-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA, S.A. (FR) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | PROC, GLS, NLN | CDC25B 3726/4885NPC1 1022/4885RAB9A 1436/4885 |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | CDC25B 3726/4885NPC1 1022/4885RAB9A 1436/4885 |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | CDC25B 846/4885NPC1 3149/4885RAB9A 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.